Комплаентность при терапии влагалищных дисбиозов

СтатьяМЕД СОВЕТ. 2019; № 12: 146–152. DOI:10.21518/2079-701X-2019-12-146-152

Тихомиров А. Л.^[1]

Сарсания С.И.^[2]

^[1]«Московский государственный медикостоматологический университет имени А.И. Евдокимова» Министерства здравоохранения Российской Федерации

^[2]Федеральный центр репродукции «Санта-Мария»

Высокая частота рецидивов бактериального вагиноза, несмотря на проведение противомикробной терапии, привела к поиску альтернативных методов лечения, которые можно было бы назначать совместно с уже применяющимися препаратами или в виде монотерапии. Поэтому при дисбиозах влагалища логичным и физиологичным по регулирующему влиянию на микрофлору и механизму терапевтической активности считается назначение пробиотиков. В статье приведены ситуационные клинические примеры применения пробиотика Вагилак.

биоценоз влагалища

бактериальный вагиноз

первый пероральный пробиотик

L. rhamnosus GR-1® и L. reuteri RC-14®

Candida glabrata

Clostridium difficile

Escherichia coli

Gardnerella

Lacticaseibacillus rhamnosus

Limosilactobacillus reuteri

Беременность

Бифидобактерии

Влагалище

Дисбактериоз

Женщины

Здравоохранение

Инфекции

Кинез

Клетки

Клостридии

Лактобациллы

Наблюдение

Пробиотики

Рецидив

Рост

Университеты

Человек

Тихомиров А.Л., Манухин И.Б. и соавт. Бактериальный вагиноз: Учеб. пособие. М., 2017. 49 с.

Gordon J.I., Klaenhammer T.R. A rendezvous with our microbes. Proc Natl Acad Sci USA. 2011;108(Suppl 1):4513-4515.

Eckert L.O., Moore D.E., Patton D.L. et al. Relationship of vaginal bacteria and inflammation with conception and early pregnancy loss following in-vitro fertilization. Infect Dis Obstet Gynecol. 2003;11:11-17.

Sobel J.D. Vulvovaginal candidosis. Lancet. 2007;369:1961-1971.

Austin M.N., Beigi R.H., Meyn L.A., Hillier S.L. Microbiologic response to treatment of bacterial vaginosis with topical clindamycin or metronidazole. J. Clin. Microbiol. 2005;43:4492-4497.

Bradshaw C.S., Morton A.N., Hocking J. et al. High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence. J Infect Dis. 2006;193:1478-1486.

Sullivan A., Edlund C. & Nord C.E. Effect of antimicrobial agents on the ecological balance of human microflora. Lancet infect. Dis. 2001;1:101-114.

Beerepoot M., ter Riet G., Nys S., et al. Lactobacilli vs antibiotics to prevent urinary tract infections: a randomized, double-blind, noninferiority trial in postmenopausal women. Arch Intern Med. 2012;172(9):704-712.

Ibnou-Zekri N., Blum S., Schiffrin EJ., von der Weid WT. Divergent patterns of colonization and immune response elicited from two intestinal Lactobacillus strains that display similar properties in vitro. Infect. Immun. 2003;71:428-436.

Naidu A.S., Bidlack W.R., Clemens R.A. Probiotic spectra of lactic acid bacteria (LAB). Crit. Rev. Food Sci. Nutr. 1999;39:13-26.

Silva M., Jacobus N.V., Deneke C., Gorbach S.L. Antimicrobial substance from a human Lactobacillus strain. Antimicrob. Agents Chemother. 1987;31:1231-1233.

Strom K., Sjogren J., Broberg A., Schnurer J. Lactobacillus plantarum MiLAB 393 produces the antifungal cyclic dipeptides cyclo(L-Phe-L-Pro) and cyclo(LPhe-trans-4-OH-L-Pro) and 3-phenyllactic acid. Appl. Environ. Microbiol. 2002;68:4322-4327.

Pothoulakis C., Kelly C.P., Joshi M.A., Gao N., O'Keane CJ., Castagliuolo I. et al. Saccharomy-ces boulardii inhibits Clostridium difficile toxin A binding and enterotoxicity in rat ileum. Gastroenterology. 1993;104:1108-1015.

Wilson K.H., Perini F. Role of competition for nutrients in suppression of Clostridium difficile by the colonic microflora. Infect. Immun. 1988;56:2610-2614.

Collado M.C., Meriluoto J., Salminen S. Role of commercial probiotic strains against human pathogen adhesion to intestinal mucus. Lett. Appl. Microbiol. 2007;45:454-460.

de Vrese M., Winkler P, Rautenberg P, Harder T., Noah C., Laue C. et al. Effect of Lactobacillus gasseri PA 16/8, Bifidobacterium longum SP 07/3, B. bifidum MF 20/5 on common cold episodes: a double blind, randomized, controlled trial. Clin. Nutr. 2005;24:481-491.

Winkler P., de Vrese M., Laue C., Schrezenmeir J. Effect of a dietary supplement containing probiotic bacteria plus vitamins and minerals on common cold infections and cellular immune parameters. Int. J. Clin. Pharmacol. Ther. 2005;43:318-326.

Reid G., Jass J., Sebulsky M.T., McCormick J.K. Potential uses of probiotics in clinical practice. Clin. Microbiol. Rev. 2003;16:658-672.

Matsuzaki T., Yamazaki R., Hashimoto S., Yokokura T. The effect of oral feeding of Lactobacillus casei strain Shirota on immunoglobulin E production in mice. J. Dairy Sci. 1998;81:48-53.

Matsuzaki T., Chin J. Modulating immune responses with probiotic bacteria. Immunol. Cell Biol. 2000;78:67-73.

Madsen K., Cornish A., Soper P. et al. Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology. 2001;121:580-591.

Chiang B.L., Sheih Y.H., Wang L.H., Liao C.K., Gill H.S. Enhancing immunity by dietary consumption of a probiotic lactic acid bacterium (Bifidobacterium lactis HN019): optimization and definition of cellular immune responses. Eur. J. Clin. Nutr. 2000;54:849-855.

Gill H.S., Rutherfurd KJ., Cross M.L., Gopal P.K. Enhancement of immunity in the elderly by dietary supplementation with the probiotic Bifidobacterium lactis HN019. Am. J. Clin. Nutr. 2001;74:833-839.

Cross M.L., Mortensen R.R., Kudsk J., Gill H.S. Dietary intake of Lactobacillus rhamnosus HNOO1 enhances production of both Th1 and Th2 cytokines in antigen-primed mice. Med. Microbiol. Immunol. (Berl). 2002;191:49-53.

Donders G.G. Treatment of bacterial vaginosis: what we have and what we miss. Expert Opin Pharmacother. 2014;15(5):645-657. [PMID: 24579850.].

Vujic G. Efficacy of orally applied probiotic capsules for bacterial vaginosis and other vaginal infections: a double-blind, randomized, placebo-controlled study Goran. Eur. J. Obstet. Gynecol. Reprod. Biol. 2013;168(1):75-79. [PMID: 23395559.]

Chew S.Y., Cheah Y.K., Seow H.F., Sandai D. and Than L.T.L. Probiotic Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14 exhibit strong antifungal effects against vulvovaginal candidiasis - causing Candida glabrata isolates. J. Appl. Microbiol. 2015;118(5):1180-1190.

Mezzasalma V., Manfrini E., Ferri E., Boccarusso M., Di Gennaro P., Schiano I., Michelotti A., Labra M. Orally administered multispecies probiotic formulations to prevent uro-genital infections: a randomized placebo-controlled pilot study. Arch Gynecol Obstet. 2017;295(1):163-172.

Язык текста: Русский

ISSN: 2079-701X